Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233


Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.

Zheng X, He K, Zhang L, Yu J.

Mol Cancer Ther. 2013 May;12(5):777-86. doi: 10.1158/1535-7163.MCT-12-1146. Epub 2013 Feb 20.


Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.

Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J, Zhang L.

Oncogene. 2012 Nov 15;31(46):4848-58. doi: 10.1038/onc.2011.644. Epub 2012 Jan 30.


Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.

Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K.

Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.


Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.

Chen D, Wei L, Yu J, Zhang L.

Clin Cancer Res. 2014 Jul 1;20(13):3472-84. doi: 10.1158/1078-0432.CCR-13-2944. Epub 2014 Apr 24.


Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells.

Sun J, Knickelbein K, He K, Chen D, Dudgeon C, Shu Y, Yu J, Zhang L.

Mol Cancer Ther. 2014 May;13(5):1298-308. doi: 10.1158/1535-7163.MCT-13-0846. Epub 2014 Feb 21.


PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.

Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J.

Oncogene. 2009 Jun 18;28(24):2348-57. doi: 10.1038/onc.2009.108. Epub 2009 May 4.


PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Dudgeon C, Wang P, Sun X, Peng R, Sun Q, Yu J, Zhang L.

Mol Cancer Ther. 2010 Nov;9(11):2893-902. doi: 10.1158/1535-7163.MCT-10-0635. Epub 2010 Oct 26.


The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.

Sun J, Sun Q, Brown MF, Dudgeon C, Chandler J, Xu X, Shu Y, Zhang L, Yu J.

PLoS One. 2012;7(8):e43158. doi: 10.1371/journal.pone.0043158. Epub 2012 Aug 17.


The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells.

Wang X, Li M, Wang J, Yeung CM, Zhang H, Kung HF, Jiang B, Lin MC.

Biochem Pharmacol. 2006 May 28;71(11):1540-50. Epub 2006 Apr 3.


Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax.

He K, Zheng X, Zhang L, Yu J.

Mol Cancer Ther. 2013 Nov;12(11):2559-68. doi: 10.1158/1535-7163.MCT-13-0284. Epub 2013 Aug 21.


Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY.

Anticancer Drugs. 2013 Nov;24(10):1039-46. doi: 10.1097/CAD.0000000000000011.


Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.

Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PW.

Cell Death Dis. 2013 Sep 5;4:e791. doi: 10.1038/cddis.2013.307.


Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.

Ray RM, Bhattacharya S, Johnson LR.

Apoptosis. 2011 Jan;16(1):35-44. doi: 10.1007/s10495-010-0538-0.


Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.


The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ.

Mol Med. 2011;17(11-12):1262-74. doi: 10.2119/molmed.2011.00176. Epub 2011 Aug 19.


Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, Shetty B.

J Pharmacol Exp Ther. 2012 Mar;340(3):549-57. doi: 10.1124/jpet.111.188870. Epub 2011 Nov 30.


ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.

Sun Y, Nowak KA, Zaorsky NG, Winchester CL, Dalal K, Giacalone NJ, Liu N, Werner-Wasik M, Wasik MA, Dicker AP, Lu B.

Mol Cancer Ther. 2013 May;12(5):696-704. doi: 10.1158/1535-7163.MCT-12-0868. Epub 2013 Feb 26.


Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells.

Liu HF, Hsiao PW, Chao JI.

Chem Biol Interact. 2008 Oct 22;176(1):48-57. doi: 10.1016/j.cbi.2008.07.012. Epub 2008 Aug 8.


Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways.

Yamaguchi H, Chen J, Bhalla K, Wang HG.

J Biol Chem. 2004 Sep 17;279(38):39431-7. Epub 2004 Jul 19.


EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.

Cancer Res. 2013 Apr 15;73(8):2428-34. doi: 10.1158/0008-5472.CAN-12-3479. Epub 2013 Feb 4.

Items per page

Supplemental Content

Write to the Help Desk